Acrivon Therapeutics, Inc. (ACRV) stock
ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$1.56+0.13 (+9.09%)
Close on Nov 18, 2026Market cap $66.85MP/E –Yield –
Acrivon Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Acrivon Therapeutics's total assets was $99.09M at Jun 30, 2026. For fiscal 2025 it was $129.72M, down 34.0% from the year before. The highest annual figure on record is $196.59M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $129.72M | -34.0% |
| FY2024 | Dec 31, 2024 | $196.59M | +42.2% |
| FY2023 | Dec 31, 2023 | $138.27M | -23.7% |
| FY2022 | Dec 31, 2022 | $181.23M | +70.0% |
| FY2021 | Dec 31, 2021 | $106.59M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $99.09M | -37.5% |
| Q1 FY2026 | Mar 31, 2026 | $107.83M | -38.9% |
| Q4 FY2025 | Dec 31, 2025 | $129.72M | -34.0% |
| Q3 FY2025 | Sep 30, 2025 | $145.30M | -32.3% |
| Q2 FY2025 | Jun 30, 2025 | $158.58M | -31.2% |
| Q1 FY2025 | Mar 31, 2025 | $176.35M | +46.3% |
| Q4 FY2024 | Dec 31, 2024 | $196.59M | +42.2% |
| Q3 FY2024 | Sep 30, 2024 | $214.68M | +42.1% |
| Q2 FY2024 | Jun 30, 2024 | $230.59M | +44.1% |
| Q1 FY2024 | Mar 31, 2024 | $120.52M | -29.2% |
| Q4 FY2023 | Dec 31, 2023 | $138.27M | -23.7% |
| Q3 FY2023 | Sep 30, 2023 | $151.09M | +72.3% |
| Q2 FY2023 | Jun 30, 2023 | $160.05M | +50.2% |
| Q1 FY2023 | Mar 31, 2023 | $170.20M | – |
| Q4 FY2022 | Dec 31, 2022 | $181.23M | – |
| Q3 FY2022 | Sep 30, 2022 | $87.71M | – |
| Q4 FY2021 | Dec 31, 2021 | $106.59M | – |
See a number that looks wrong?